Deutsche Märkte geschlossen

ARK Innovation ETF (ARKK)

NYSEArca - NYSEArca Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
99,18+0,60 (+0,61%)
Börsenschluss: 4:00PM EDT
Melden Sie sich an, um eine Nachricht zu posten.
  • A
    Adam
    $ARKK conversation
    Earlier this month I bought open calls for $ARKG $80 Jan and $ARKK $110 Dec.
    Are these still within reach? Cut my losses now? Wait for the election?
  • L
    Lulu
    Nikola Corporation
    1 hydrogen station is around $15-20m per station. GM deal is $700m. Arizona factory is $600m. weekly burn rate us around $5m. Nikola cash today is under $700m. Why buy nikola? go buy $NIO, $TSLA, $BYDDF, $XPEV or $ARKK instead. nikola is a high bankruptcy risk.
  • V
    VirginiaLova
    $CRSP conversation
    The dumb investor says “I wish I purchased at 80.”
    The smart investor says I am buying under $200. The most competent analyst covering this stock is at Suntrust. That analyst is 1) a microbiology major 2) a doctor 3) Harvard medical residency 4) and four months ago wrote a 50 page report valuing CRISPR THERAPEUTICS at $140 per share. But that was before the 2020 Nobel Prize award which has quieted all noise about the technology, and, in fact, awkwardly suggests that using Crispr to cure cancer is imminent (SUNTRUST ANALYSIS is Predominantly on Cancer Cure Potential and that there are three active clinical trials testing “off the shelf” Car-T cures). More importantly, there is proof of concept in Victoria Gray, and; the 7 other patients dosed (good NPR articles on Victoria’s progress). Returning to cancer, the implications for the cancer treatment is that it will be monumental in medicine, as they use healthy donor cells, edit those cells to attack the cancer, and take it “off the shelf” to quickly administer a treatment to a cancer patient. Cancer, DMD, CF, SCD, BT, and countless other diseases is what Crispr is focused on. Many of the programs they are working on are proprietary and kept secret 🤫 ... Crispr under $200 is a no brainer. I expect this stock to move quickly through the target of Suntrust $140 ... the street will be re eating this stock to $190 at $150 ... and that is when you see the constant cycle of upgrades as the market cap on this stock could realistically be $1T. This isn’t a cancer stock. This isn’t a HIV stock. This is a cure all disease stock. Finally, of course it is a top four holding of $ARKK. And it is the top holding of $ARKG. Cathie Wood projects this technology as a multi trillion dollar business. She was correct on Tesla $Tsla (calling for $2000 a share at $200 per share — pre split). It looks like she got this one right too — top holding in $ARKG — this may become her second largest holding in $ARKK VERY very quickly. Good luck. Be long. Own this. Don’t trade this.
  • F
    Fallen Knife
    NIO NEW PT40 by JP Morgan. Next, I want to see news of $ARKK buys $NIO. Cathiee Pleaaaase.
  • V
    VirginiaLova
    $CRSP conversation
    Cramer Tonight — Crispr Therapeutics: “Crispr’s the real deal, and I think you’ve got a very good one and I like it very much”

    $CRSP $VRTX $ARKK $ARKG
  • A
    Adam
    $ARKK conversation
    Here are some stocks I would like to see Cathy consider adding to the $ARKK holdings:
    $PLUG $NIO $ENPH $SPWR $LAC
  • A
    Anonymous Green
    $BEAM conversation
    It would not surprise me if in the near future BEAM ended up on the $ARKK list. $EDIT $NTLA $CRSP
  • W
    WallSt.
    $WORK conversation
    Seems that $ArkK is buying $Work. Today Cathie Wood is Warren Buffet in his prime. She is smart and has a great team of young research.
  • V
    VirginiaLova
    $WORK conversation
    Did you see $ARKK Cathie Wood purchased another 393,000 SHARES of Slack today, or, $11M in Slack. What does she know?
  • V
    VirginiaLova
    $WORK conversation
    $ARKK another buy of $Work today
  • J
    Jared
    Markets going up 5% tomorrow:

    CANCEL ALL SELL ORDERS FOR TOMORROW MORNING

    #BRK-B #AMD #RVLV #VGLT #VWO #ARKK #AMZN #TSLA #AAPL #CIBR #NVTA #MAIN #VYM #KR #TXRH #SPXL #
  • V
    VirginiaLova
    $CRSP conversation
    Today, Roth Capital Issued a BUY rating on Crispr Therapeutics with a $105 price target. $VRTX $TSLA $EDIT $NTLA $ARKG $ARKK
  • V
    VirginiaLova
    $CRSP conversation
    $CRSP $Arkk $Tsla $Vrtx Huge news out of the FDA FOR CRISPR Therapeutics and Regeneron
  • J
    Joe
    $MGTI conversation
    $ARKK initiated a new position in $MGTI on 1/12/18. Very positive news!
  • V
    VirginiaLova
    $CRSP conversation
    Two patients suffering from beta-thalassemia and one patient suffering from sickle cell disease no longer require blood transfusions to treat these disease with the help of CRISPR.
    Two patients suffering from beta-thalassemia and one patient suffering from sickle cell disease no longer require blood transfusions to treat these disease with the help of CRISPR.
    www.google.com
  • V
    VirginiaLova
    $CRSP conversation
    For years, I consistently urged investors to focus the bulk of their portfolios on what I term “megatrends.” While making a quick buck on momentum plays is great, your highest probabilities of success rest on long-term developments in technology and
    For years, I consistently urged investors to focus the bulk of their portfolios on what I term “megatrends.” While making a quick buck on momentum plays is great, your highest probabilities of success rest on long-term developments in technology and
    currentstocktrends.com
  • V
    VirginiaLova
    $CRSP conversation
    Another 31k shares $crsp purchased in 60-61.4 range yesterday By $ARKK $Arkg
  • W
    WallSt.
    $WKHS conversation
    $ArkK invest should be take possession of $WKHS
  • A
    Alfyee
    $QCLN conversation
    This is a good ETF that outperform $ARKK from Jun-Jul 2020, with good quarterly dividend. :)
  • j
    james
    $FAZ conversation
    Really can't add to this. People are not seeing reality.
    https://news.yahoo.com/stunning-layoff-figures-11-states-120612199.html
    #NVDA, #BA, #INTC,# SPCE, #AVGO,#CRWD, #ARKW, #ARKK, #AMD, ETC.
    There is a surge of people seeking unemployment benefits across the country as the coronavirus forces businesses to close and triggers layoffs.
    There is a surge of people seeking unemployment benefits across the country as the coronavirus forces businesses to close and triggers layoffs.
    news.yahoo.com